Cellosaurus HEK293SF-3F6 (CVCL_4V95)
| Cell line name | HEK293SF-3F6 | ||
|---|---|---|---|
| Synonyms | HEK293-SF-3F6; HEK 293SF-3F6; 293SF-3F6 | ||
| Accession | CVCL_4V95 | ||
| Resource Identification Initiative | To cite this cell line use: HEK293SF-3F6 (RRID:CVCL_4V95) | ||
| Comments | Group: Patented cell line. Group: Serum/protein free medium cell line. Group: Vaccine production cell line. Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12585. Biotechnology: Used for the production of the CanSino Biologics Ebola virus vaccine (Trade name: Ad5-EBOV). Biotechnology: Used for the production of the CanSino Biologics SARS-CoV-2 (COVID-19) vaccine (Trade name: Convidecia; also known as Ad5-nCOV) (DrugBank=DB15655). Transformant: NCBI_TaxID; 28285; Adenovirus 5. Derived from site: In situ; Fetal kidney; UBERON=UBERON_0002113. | ||
| Species of origin | Homo sapiens (Human) (NCBI Taxonomy: 9606) | ||
| Hierarchy | Parent: CVCL_4V94 (HEK293SF) Children:
| ||
| Sex of cell | Female | ||
| Age at sampling | Fetus | ||
| Category | Transformed cell line | ||
| Web pages | Info; NRC Canada; -; https://www.canada.ca/en/national-research-council/news/2020/05/the-national-research-council-of-canada-and-cansino-biologics-inc-announce-collaboration-to-advance-vaccine-against-covid-19.html Provider; NRC Canada; 10894; https://nrc.canada.ca/en/research-development/intellectual-property-licensing/hek293sf-3f6-hek293-6e-expression-platforms-l-10894-11266-11565 | ||
| Publications | PubMed=10099373; DOI=10.1002/(SICI)1097-0290(19980905)59:5<567::AID-BIT6>3.0.CO;2-8 Patent=US6210922 PubMed=31548015; DOI=10.1016/j.vaccine.2019.09.044 | ||
| Cross-references | |||
| Cell line collections (Providers) | ATCC; CRL-3537
ATCC; CRL-12585 - Discontinued | ||
| Encyclopedic resources | Wikidata; Q54882487 | ||
| Entry history | |||
| Entry creation | 14-Dec-2015 | ||
| Last entry update | 10-Apr-2025 | ||
| Version number | 13 | ||